What does the evidence say about Policosanol Blood Pressure Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Policosanol Blood Pressure Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - It is concluded that oral administration of policosanol 20 mg/day for twelve weeks significantly lowered SBP and DBP in Cuban patients with grade I hypertension, and improved lipid profile variables, being safe and well tolerated. [Revueltas Aguero M (2025); evidence level 2] - This study aimed to report the effects of policosanol (20 mg/day) on blood pressure values in Cuban patients with grade I hypertension. [Revueltas Aguero M (2025); evidence level 2] - A double-blind multicenter trial randomized 400 eligible patients divided into two strata of patients with either prehypertension or grade I hypertension (200 patients each) treated with either placebo or policosanol 20 mg/day (100 patients/group/stratum) for 12 weeks. [Revueltas Aguero M (2025); evidence level 2] - 1 2 Hypertension is the most frequent modifiable cardiovascular risk factor, with more than 1 billion individuals living with high blood pressure worldwide []. [Revueltas Moura (2025); evidence level 2] - 3 Evidence has proven the impact of lowering blood pressure for improving cardiovascular outcomes and all‐cause mortality [], making clear the relevance of promoting knowledge, prevention, and treatment of high blood pressure levels. [Revueltas Moura (2025); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.